Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | Fluzoparib |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Fluzoparib | HS10160|SHR-3162|SHR3162 | PARP Inhibitor (Pan) 22 | Fluzoparib (SHR3162) is a PARP inhibitor, which potentially induces DNA damage, cell cycle arrest and apoptosis, and inhibits cell proliferation and tumor growth (PMID: 30663191, PMID: 32694901). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| Unknown unknown | breast cancer | not applicable | Fluzoparib | Phase I | Actionable | In a Phase I trial, Fluzoparib treatment was well tolerated, and among evaluable breast cancer patients resulted in an overall response rate (ORR) of 7.7% (1/13) and stable disease at 24 weeks in 5/13, for a disease control rate of 23.1%, and a median progression-free survival (mPFS) of 3.5 months in patients dosed at >120mg/d, with 1 patient still on treatment at 28 months (PMID: 32694901; NCT03509636). | 32694901 |
| Unknown unknown | ovarian cancer | not applicable | Fluzoparib | Preclinical - Cell culture | Actionable | In a preclinical study, Fluzoparib inhibited DNA-damage-induced PARylation in high-grade serous ovarian cancer cell lines in culture, however, the cells demonstrated resistance to Fluzoparib treatment (PMID: 30949414). | 30949414 |
| Unknown unknown | ovarian cancer | not applicable | Fluzoparib | Phase I | Actionable | In a Phase I trial, Fluzoparib treatment was well tolerated, and among evaluable ovarian cancer patients resulted in an overall response rate (ORR) of 8.1% (3/37) and stable disease at 24 weeks in 14/37, for a disease control rate of 45.9%, and a median progression-free survival (mPFS) of 7.2 months in patients dosed at >120mg/d, with an ORR of 30% (3/10) and mPFS of 9.3 months in platinum-sensitive patients (PMID: 32694901; NCT03509636). | 32694901 |
| Unknown unknown | triple-receptor negative breast cancer | not applicable | Fluzoparib | Preclinical - Cell culture | Actionable | In a preclinical study, Fluzoparib inhibited DNA-damage-induced PARylation in breast cancer cell lines in culture, however, the cells demonstrated resistance to Fluzoparib treatment (PMID: 30949414). | 30949414 |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|
CKB BOOST